About Dr. Xie Weifen
Dr. Xie Weifen (谢渭芬) is one of China's most distinguished hepatologists and the Director of the Department of Gastroenterology and Hepatology at Zhongshan Hospital, affiliated with Fudan University. He holds the title of Chief Physician and Professor and is nationally recognized as a leading authority on viral hepatitis, liver fibrosis, and non-alcoholic fatty liver disease.
Over a career spanning more than three decades, Dr. Xie has established himself as one of China's foremost clinical researchers in hepatology, with landmark contributions to the understanding of liver fibrosis regression, hepatitis B natural history, and NAFLD pathogenesis. His research demonstrating that liver fibrosis — long considered irreversible — can regress with effective antiviral therapy has been one of the most impactful findings in Chinese hepatology and has directly influenced treatment guidelines worldwide.
International patients with chronic hepatitis B or C, liver fibrosis, cirrhosis, or NAFLD consistently identify Dr. Xie as one of China's top hepatologists for both primary treatment and expert second opinions.
Professional Positions and Affiliations
- Director, Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University
- Chairman, Liver Fibrosis Committee, Chinese Society of Hepatology
- Vice Chairman, Chinese Society of Hepatology
- Editorial Board Member: Journal of Hepatology, Hepatology, Liver International, Journal of Gastroenterology and Hepatology
- Member, European Association for the Study of the Liver (EASL)
- Member, Asian Pacific Association for the Study of the Liver (APASL)
- Member, American Association for the Study of Liver Diseases (AASLD)
Specialties and Clinical Expertise
- Chronic Hepatitis B — antiviral therapy optimization (TAF, entecavir, TDF); functional cure strategies; treatment cessation criteria; management in special populations (pregnancy, immunosuppression, renal impairment, co-infection)
- Chronic Hepatitis C — pan-genotypic DAA therapy; treatment of cirrhotic and post-transplant patients; SVR assessment and post-cure HCC surveillance
- Liver Fibrosis and Cirrhosis — non-invasive fibrosis assessment (FibroScan, ELF panel, FIB-4); liver biopsy interpretation; antifibrotic therapy; fibrosis regression monitoring after antiviral treatment
- Non-Alcoholic Fatty Liver Disease (NAFLD/NASH) — metabolic risk stratification, liver biopsy, fibrosis staging, and emerging pharmacotherapy (resmetirom, semaglutide, lanifibranor)
- Autoimmune Liver Disease — autoimmune hepatitis, primary biliary cholangitis, and overlap syndromes
- Portal Hypertension and Cirrhosis Complications — variceal bleeding, ascites, hepatic encephalopathy, and hepatorenal syndrome management
- HCC Surveillance — ultrasound and AFP-L3/DCP biomarker-based surveillance for cirrhotic patients; coordination with interventional radiology and hepatobiliary surgery
- Drug-Induced Liver Injury (DILI) — causality assessment and management; herbal medicine-induced liver injury
Academic and Research Contributions
Dr. Xie Weifen has published over 200 peer-reviewed papers in leading international hepatology journals. His most celebrated research — demonstrating histological regression of liver fibrosis and even cirrhosis in chronic hepatitis B patients treated with long-term antiviral therapy — has been published in Hepatology and Journal of Hepatology and has been cited thousands of times internationally. This work fundamentally changed the understanding of liver fibrosis as a dynamic, potentially reversible process and has influenced treatment guidelines from EASL, AASLD, and APASL.
He chairs the Liver Fibrosis Committee of the Chinese Society of Hepatology and has been a lead author on China's national liver fibrosis management guidelines. He serves on the editorial boards of Journal of Hepatology, Hepatology, and Liver International, and is a regular invited speaker at EASL, AASLD, and APASL annual congresses.
Why International Patients Choose Dr. Xie Weifen
- Liver fibrosis regression pioneer — his research changed global understanding of fibrosis reversibility
- China's leading hepatitis B natural history expert — decades of longitudinal cohort data
- Journal of Hepatology and Hepatology editorial board — at the forefront of global hepatology research
- EASL, AASLD, and APASL member — aligned with all major international hepatology guidelines
- Non-invasive fibrosis assessment expertise — FibroScan and biomarker-based staging to minimize need for liver biopsy
- English-language support available through CMCS concierge coordination
Practical Information for International Patients
- Hospital: Zhongshan Hospital, 180 Fenglin Road, Xuhui District, Shanghai
- Appointment Lead Time: 2″4 weeks; urgent cases expedited through CMCS
- Languages: Mandarin Chinese; English interpretation provided by CMCS
- Pre-consultation: Overseas lab results, FibroScan reports, and liver biopsy results reviewed remotely through CMCS
How CMCS Can Help
China Medical Concierge Shanghai (CMCS) provides end-to-end support for international patients seeking hepatology care with Dr. Xie Weifen at Zhongshan Hospital. Our services include priority appointment booking, medical record and lab result translation, remote pre-consultation review, on-site interpretation, accommodation coordination, insurance liaison, and post-treatment follow-up with your home country hepatologist.
📧 Contact us: contract@medicalsh.com
🌐 medicalsh.com
0 則留言